Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEMEYA vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
FDA-approved: Treatment of moderate to severe rheumatoid arthritis in adult patients with an inadequate response to methotrexate.,Off-label: Not typically used off-label due to limited data.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life: 12-15 hours; Clinical context: allows twice-daily dosing; prolonged in renal impairment (up to 24-30 hours in Cr Cl <30 m L/min)
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Forms inactive metabolites.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~70% as unchanged drug; Fecal: ~20% as metabolites; Biliary: <10%
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
High: ~95% bound to albumin and alpha-1-acid glycoprotein
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Vd: 3-5 L/kg; indicates extensive tissue distribution
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 80-90%
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
Contraindicated if Cr Cl <35 m L/min; for osteoporosis, not recommended if Cr Cl <35 m L/min. No dose adjustment needed for Cr Cl >=35 m L/min.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No specific dose adjustment required for hepatic impairment; caution in severe hepatic impairment due to limited data.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy not established in children; no approved pediatric dosing.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific dose adjustment for elderly; monitor renal function as age-related decline in Cr Cl may necessitate avoidance if Cr Cl <35 m L/min.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, AND THROMBOSIS. Patients treated with KEMEYA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants. If a serious infection develops, interrupt KEMEYA until the infection is controlled. Reported infections include active tuberculosis, invasive fungal infections, and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been observed. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have been reported. Consider risks vs benefits before initiating therapy.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Risk of serious infections, including tuberculosis and invasive fungal infections.,Avoid use in patients with active infections.,Monitor for signs and symptoms of infection during treatment.,Risk of thrombosis: Use with caution in patients with risk factors for thrombosis.,Risk of malignancy, particularly lymphoma.,Hepatotoxicity: Monitor liver enzymes regularly.,Cytopenias: Monitor complete blood counts at baseline and periodically.,Gastrointestinal perforations have been reported; monitor for abdominal pain.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to the active substance or any excipients.,Active serious infections, including localized infections.,Known active tuberculosis.,Severe hepatic impairment (Child-Pugh C).,Pregnancy (based on animal studies showing fetal harm).
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food restrictions. Grapefruit product interactions are not clinically significant. Avoid estrogen-containing foods (e.g., soy supplements) as they may reduce efficacy.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Teratogenic effects have been observed in animal reproduction studies at doses below the recommended human dose. In particular, exposure during the first trimester is associated with major congenital malformations, including neural tube defects, craniofacial abnormalities, and cardiovascular defects. During the second and third trimesters, fetal growth restriction and oligohydramnios may occur.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
It is not known whether KEMEYA is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from KEMEYA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The milk-to-plasma (M/P) ratio has not been determined for KEMEYA.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Due to the risk of fetal harm, KEMEYA is contraindicated in pregnancy, and no dose adjustments are recommended. If inadvertent exposure occurs during pregnancy, the drug should be discontinued immediately. The pharmacokinetics of KEMEYA in pregnant women have not been studied, and thus no specific dosing guidelines for pregnancy exist.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
KEMEYA (letrozole) is an aromatase inhibitor used for hormone receptor-positive breast cancer. Monitor for bone mineral density loss and consider bisphosphonates. Not effective in estrogen receptor-negative tumors. Avoid in premenopausal women without concurrent ovarian suppression. Dose adjustment needed in severe hepatic impairment (Child-Pugh C).
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take exactly as prescribed, usually once daily without regard to meals.,Report any new bone pain, joint stiffness, or fractures promptly.,Use effective non-hormonal contraception if premenopausal; letrozole can cause fetal harm.,May cause hot flashes, fatigue, and night sweats; these are not dangerous.,Do not take estrogen-containing medications or supplements while on letrozole.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEMEYA vs ALTAVERA, answered by our medical review team.
KEMEYA is a Oral Contraceptive that works by Selective inhibitor of Janus kinase 1 (JAK1), modulating the JAK-STAT signaling pathway to reduce pro-inflammatory cytokine production.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEMEYA and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEMEYA is: KEMEYA (zoledronic acid) 5 mg intravenously once yearly for osteoporosis. For Paget disease, 5 mg intravenously as a single dose.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEMEYA and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEMEYA is classified as Category C. KEMEYA is contraindicated in pregnancy. Based on animal studies and its mechanism of action, KEMEYA may cause fetal harm when administered to a pregnant woman. There are no adequat. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.